Haleon Pakistan Limited is set to invest £3.58 million ($4.9 million USD) and 1.35 Billion PKR to expand and modernize its Panadol Liquid packaging line, a move aimed at meeting rising demand in the local pharmaceutical market. The investment, approved by the company’s board of directors, will enhance production capacity, operational efficiency, and quality control standards.
Panadol, a widely used pain-relief and fever-reducing medicine, has been a key product in Pakistan’s over-the-counter healthcare segment. With growing consumer demand for liquid formulations, Haleon Pakistan is upgrading its manufacturing infrastructure to maintain consistent supply and product quality.
The expansion project will involve the procurement of advanced packaging machinery, upgrades to existing facilities, and improvements in quality control systems. According to the company, these measures are part of a broader strategy to strengthen its manufacturing capabilities and support long-term growth in the consumer healthcare sector.
Haleon Pakistan said the initiative reflects its commitment to innovation while ensuring that Panadol Liquid remains readily available to meet market needs. The company’s efforts to modernize production underline its focus on operational excellence and sustaining a competitive position in Pakistan’s pharmaceutical industry.